TNI BioTech, Inc. (TNIB) Secures the Exclusive Rights to Low Dose Naltrexone and Other Opioid Antagonists
Earlier today, TNI BioTech announced that it has entered into an agreement to acquire patent rights to a novel late-stage drug, trademarked “LDN,” for the treatment of Pediatric Crohn’s Disease. The patent acquired covers methods and formulations for treatment of the inflammatory and ulcerative diseases of the bowel, using naltrexone in low dose as an opioid antagonist. Endogenous opioids and opioid antagonists have been shown to play a role in stimulating and rebalancing the immune system and the healing and repair of tissues. As part of the agreement, TNI BioTech has obtained the right to apply to the Food and…